The effects of miglitol on glucagon‐like peptide‐1 secretion and appetite sensations in obese type 2 diabetics
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background: Previous studies reported that administration of first generation α‐glucosidase inhibitors (AGIs), such as voglibose or acarbose, produced exaggerated and sustained postprandial responses of glucagon‐like peptide‐1 (GLP‐1), an incretin hormone from the enteroinsular axis, in healthy humans. Little is known about the postprandial release of GLP‐1 after AGI therapy in diabetics. GLP‐1 plays a role to mediate satiety. Any agent that substantially elevates GLP‐1 levels may theoretically reduce hunger, increase satiation and limit food intake. Objectives: This study was performed to analyse the effect of miglitol, a more potent second generation AGI with fewer gastrointestinal side‐effects, on the regulation of meal‐related GLP‐1 secretion and on the change of insulin–glucose dynamics as well as the release of gastric inhibitory polypeptide (GIP), another incretin hormone, after stimulation by an ordinary meal in obese type‐2‐diabetic subjects. Miglitol's subsequent influences on appetite sensations and food intake were also measured. Design: In total, 8 obese type‐2‐diabetic women were randomized to receive treatment with 100 mg of miglitol or placebo three times a day for 2 days (six doses total) in a double‐blind fashion. On day 3 of each treatment period (miglitol or placebo), measurements of GLP‐1, GIP, insulin and glucose were taken periodically during 3 h after eating a 720 kcal breakfast. Appetite ratings with visual analogue scales (VASs) were used to assess ingestive behaviour hourly just before breakfast and hourly after for 6 h until immediately before lunch. The number of tuna sandwiches eaten at lunch was used to measure food consumption. Results: The plasma GLP‐1, glucose, insulin and GIP levels in response to the mixed meal were compared after the miglitol and placebo treatment. Miglitol effectively enhanced postprandial GLP‐1 release and suppressed plasma GIP secretion. The ingestion of a mixed meal induced a remarkable rise in GLP‐1 after miglitol as compared with placebo in overweight diabetic subjects. The meal‐related rise in GLP‐1 after miglitol was significantly greater at all time‐points between 30 and 180 min than after the placebo. The postprandial incremental area under the curve for GLP‐1 with miglitol treatment was about twofold that with the placebo. The GLP‐1 level reached a maximum at 120 min after the mixed meal and steadily rose throughout the rest of the 3‐h study period. In the miglitol‐treated condition, the average caloric intake at lunch during a 30‐min eating period was 12% lower (p < 0.05) as compared with that after the placebo in six out of the eight subjects who exhibited a GLP‐1 rise after the breakfast meal by greater than 30% from the placebo‐treated condition. Correspondingly, the average rating scores were significantly lower for hunger feelings and markedly greater for sensations of satiety under the miglitol treatment; beginning 2 and 3 h, respectively, before the lunch test. Conclusions: Miglitol induced an enhanced and prolonged GLP‐1 release at high physiological concentrations after ingesting an ordinary meal in glycaemic‐controlled diabetics. The excessive postprandial GLP‐1 elevation after miglitol therapy modified feeding behaviour and food intake, and thereby has potential value in regulating appetite and stabilizing body weight in obese type‐2‐diabetic patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
Göke, R., Larsen, P. J., Mikkelsen, J. D., & Sheikh, S. P. (1995) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1995.tb00650.x · Cited by 474
Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.
Näslund, E., Barkeling, B., King, N., Gutniak, M., Blundell, J., Holst, J., Rössner, S., & Hellström, P. (1999) · International Journal of Obesity · doi:10.1038/sj.ijo.0800818 · Cited by 468
Attenuated GLP-1 secretion in obesity: cause or consequence
Ranganath, L. R., Beety, J. M., Morgan, L. M., Wright, J. W., Howland, R., & Marks, V (1996) · Gut · doi:10.1136/gut.38.6.916 · Cited by 394
Lee, A., & Morley, J. E. (1998) · Obesity Research · doi:10.1002/j.1550-8528.1998.tb00314.x · Cited by 320
Self-citation
Cited by
Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347
“-Glucosidase inhibitors such as acarbose and miglitol may be weight neutral or lead to a small change in weight (152, 153).”
BackgroundSecretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
Nauck, M. A., Vardarli, I., Deacon, C. F., Holst, J. J., & Meier, J. J. (2011) · Diabetologia · doi:10.1007/s00125-010-1896-4 · Cited by 465
“This may be different with second-generation α-glucosidase inhibitors such as voglibose [60] and miglitol [61].”
BackgroundHuman duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP
Theodorakis, M. J., Carlson, O., Michopoulos, S., Doyle, M. E., Juhaszova, M., Petraki, K., & Egan, J. M. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00326.2004 · Cited by 396
A review of the efficacy and safety of oral antidiabetic drugs
Stein, S. A., Lamos, E. M., & Davis, S. N. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.752813 · Cited by 305
Diabetes, Sarcopenia, and Frailty
Morley, J. E. (2008) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2008.03.004 · Cited by 186
“The alpha-1-glucosidase inhibitors release glucagon-like peptide 1 which slows gastric emptying [56].”
BackgroundSelf-citation
Metadata
- Authors
- Lee, A., Patrick, P., Wishart, J., Horowitz, M., & Morley, J. E.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2002-08-19
- Volume
- 4
- Issue
- 5
- Pages
- 329-335
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2080499100
- Cited by
- 150
- References
- 5
- FWCI
- 1.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The effects of miglitol on glucagon‐like peptide‐1 secretion and appetite sensations in obese type 2 diabetics. https://app.cochat.ai/papers/10.1046/j.1463-1326.2002.00219.x
- The paper
- Lee, A., Patrick, P., Wishart, J., Horowitz, M., & Morley, J. E. (2002). The effects of miglitol on glucagon‐like peptide‐1 secretion and appetite sensations in obese type 2 diabetics. Diabetes, Obesity and Metabolism. https://doi.org/10.1046/j.1463-1326.2002.00219.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.